3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Genomic Instability
1
Interventions
Oxaliplatin
10
Capecitabine
9
Cisplatin
8
Fluorouracil
5
Leucovorin
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
atezolizumab
3
Nivolumab
3
trebananib
2
ponatinib
2
pembrolizumab
2
avelumab
2
apatinib
2
alectinib
2
XELOX
2
Standard of Care
2
S 1 (combination)
2
Radiotherapy
2
Radiosurgery
2
Ocoxin
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
Folfox protocol
2
Everolimus
2
Erlotinib Hydrochloride
2
Acupuncture Therapy
2
zanidatamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Neoplasms
×
alectinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts